EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea und 16 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.01.007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Marina Y Konopleva und 27 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: mkonople@mdanderson.org. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Azetidines, Piperidines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc, F. Hoffmann-La Roche, Genentech Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. PATIENTS AND METHODS: This phase 1b trial evaluated venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, plus cobimetinib, a MEK1/2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia, ineligible for cytotoxic chemotherapy. Two-dimensional dose-escalation was performed for venetoclax dosed daily, and for cobimetinib dosed on days 1-21 of each 28-day cycle. RESULTS: Thirty patients (median [range] age: 71.5 years [60-84]) received venetoclax-cobimetinib. The most common adverse events (AEs; in ≥40.0% of patients) were diarrhea (80.0%), nausea (60.0%), vomiting (40.0%), febrile neutropenia (40.0%), and fatigue (40.0%). Overall, 66.7% and 23.3% of patients experienced AEs leading to dose modification/interruption or treatment withdrawal, respectively. The composite complete remission (CRc) rate (complete remission [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery) was 15.6%; antileukemic response rate (CRc + morphologic leukemia-free state/partial remission) was 18.8%. For the recommended phase 2 dose (venetoclax: 600 mg; cobimetinib: 40 mg), CRc and antileukemic response rates were both 12.5%. Failure to achieve an antileukemic response was associated with elevated baseline phosphorylated ERK and MCL-1 levels, but not BCL-xL. Baseline mutations in ≥1 signaling gene or TP53 were noted in nonresponders and emerged on treatment. Pharmacodynamic biomarkers revealed inconsistent, transient inhibition of the mitogen-activated protein kinase (MAPK) pathway. CONCLUSION: Venetoclax-cobimetinib showed limited preliminary efficacy similar to single-agent venetoclax, but with added toxicity. Our findings will inform future trials of BCL-2/MAPK pathway inhibitor combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesAzetidinesPiperidinesLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemaleMiddle AgedAged, 80 and overTreatment OutcomeDrug Resistance, Neoplasm

Stichwörter der Autor:innen

B-cell lymphoma-2BiomarkerMitogen-activated protein kinase pathwayTargeted therapy

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidescobimetinibAzetidinesPiperidines

Autor:innen und Institutionen

  • University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: mkonople@mdanderson.org.
  • Genentech, Inc., South San Francisco, CA.
  • University of Texas, MD Anderson Cancer Center, Houston, TX.
  • Dana-Farber Cancer Institute, Boston, MA.
  • University of California Davis Comprehensive Cancer Center, Sacramento, CA.
  • Princess Margaret Cancer Centre, Toronto, ON, Canada.

Förderung

  • AbbVie Inc
  • F. Hoffmann-La Roche
  • Genentech Inc

Zitieren

APA

Konopleva, M. Y., Dail, M., Daver, N. G., Garcia, J. S., Jonas, B. A., Yee, K. W. L., Kelly, K. R., Vey, N., Assouline, S., Roboz, G. J., Paolini, S., Pollyea, D. A., Tafuri, A., Brandwein, J. M., Pigneux, A., Powell, B. L., Fenaux, P., Olin, R. L., Visani, G., …, & Andreeff, M. (2024). Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.01.007

Vancouver

Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, et al. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.01.007

BibTeX
@article{Konopleva2024,
  author = {Konopleva, Marina Y and Dail, Monique and Daver, Naval G and Garcia, Jacqueline S and Jonas, Brian A and Yee, Karen W L and Kelly, Kevin R and Vey, Norbert and Assouline, Sarit and Roboz, Gail J and Paolini, Stefania and Pollyea, Daniel A and Tafuri, Agostino and Brandwein, Joseph M and Pigneux, Arnaud and Powell, Bayard L and Fenaux, Pierre and Olin, Rebecca L and Visani, Giuseppe and Martinelli, Giovanni and Onishi, Maika and Wang, Jue and Huang, Weize and Dunshee, Diana R and Hamidi, Habib and Ott, Marion G and Hong, Wan-Jen and Andreeff, Michael},
  title = {Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.01.007}
}
Kostenlos starten →